Astrazeneca Plc Adr Stock Performance
| AZN Stock | USD 68.55 0.19 0.28% |
AstraZeneca PLC has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.58, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AstraZeneca PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding AstraZeneca PLC is expected to be smaller as well. AstraZeneca PLC ADR right now shows a risk of 1.21%. Please confirm AstraZeneca PLC ADR value at risk, as well as the relationship between the skewness and day median price , to decide if AstraZeneca PLC ADR will be following its price patterns.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in AstraZeneca PLC ADR are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy basic indicators, AstraZeneca PLC is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.28 | Five Day Return (0.75) | Year To Date Return 0.22 | Ten Year Return 98.41 | All Time Return 1.3 K |
Forward Dividend Yield 0.0212 | Payout Ratio 0.3984 | Last Split Factor 2:1 | Forward Dividend Rate 1.45 | Dividend Date 2024-03-25 |
| AstraZeneca PLC dividend paid on 25th of March 2024 | 03/25/2024 |
1 | World 50 Group Announces Winners for the 2024 ID Impact Awards, Recognizing Workplace Excellence in Diversity, Equity, and Inclusion | 03/28/2024 |
2 | Box Named a 2024 Fortune 100 Best Companies to Work For | 04/04/2024 |
3 | Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein | 04/08/2024 |
4 | AstraZeneca shareholders approve 2024 pay policy at AGM | 04/11/2024 |
5 | Novo NordiskEli Lillys Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says | 04/12/2024 |
6 | Innate Pharma annonce la progression de lessai clinique valuant le NK Cell Engager SAR443579 IPH6101 dvelopp par Sanofi vers la Phase 2 dans divers cancers du s... | 04/15/2024 |
7 | US Rep. Jasmine Crockett warns anti-abortion advocates that Viagra could be next | 04/16/2024 |
8 | Kids need to breathe just like adults do 35 price caps dont apply to asthma meds young children need, doctors say | 04/17/2024 |
9 | Astrazeneca Could Be a Great Choice | 04/18/2024 |
| Begin Period Cash Flow | 6 B | |
| Total Cashflows From Investing Activities | -4.1 B |
AstraZeneca |
AstraZeneca PLC Relative Risk vs. Return Landscape
If you would invest 6,612 in AstraZeneca PLC ADR on January 21, 2024 and sell it today you would earn a total of 243.00 from holding AstraZeneca PLC ADR or generate 3.68% return on investment over 90 days. AstraZeneca PLC ADR is generating 0.0637% of daily returns assuming volatility of 1.2144% on return distribution over 90 days investment horizon. In other words, 10% of stocks are less volatile than AstraZeneca, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
AstraZeneca PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AstraZeneca PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AstraZeneca PLC ADR, and traders can use it to determine the average amount a AstraZeneca PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0524
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | AZN | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.21 actual daily | 10 90% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average AstraZeneca PLC is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AstraZeneca PLC by adding it to a well-diversified portfolio.
AstraZeneca PLC Fundamentals Growth
AstraZeneca Stock prices reflect investors' perceptions of the future prospects and financial health of AstraZeneca PLC, and AstraZeneca PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AstraZeneca Stock performance.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.066 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 129.78 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 5.46 X | ||||
| Price To Sales | 4.67 X | ||||
| Revenue | 45.81 B | ||||
| Gross Profit | 35.73 B | ||||
| EBITDA | 13.91 B | ||||
| Net Income | 6.9 B | ||||
| Cash And Equivalents | 4.52 B | ||||
| Cash Per Share | 1.46 X | ||||
| Total Debt | 28.62 B | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 0.81 X | ||||
| Book Value Per Share | 25.25 X | ||||
| Cash Flow From Operations | 10.35 B | ||||
| Earnings Per Share | 1.91 X | ||||
| Market Capitalization | 211.95 B | ||||
| Total Asset | 101.12 B | ||||
| Retained Earnings | 1.5 B | ||||
| Working Capital | (5.49 B) | ||||
| Current Asset | 16.01 B | ||||
| Current Liabilities | 14.87 B | ||||
About AstraZeneca PLC Performance
To evaluate AstraZeneca PLC ADR Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when AstraZeneca PLC generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare AstraZeneca Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand AstraZeneca PLC ADR market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents AstraZeneca's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 239.45 | 141.81 | |
| Return On Tangible Assets | 0.14 | 0.11 | |
| Return On Capital Employed | 0.12 | 0.11 | |
| Return On Assets | 0.06 | 0.10 | |
| Return On Equity | 0.15 | 0.14 |
Things to note about AstraZeneca PLC ADR performance evaluation
Checking the ongoing alerts about AstraZeneca PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AstraZeneca PLC ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company has 28.62 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity. | |
| AstraZeneca PLC ADR has a very strong financial position based on the latest SEC filings | |
| On 25th of March 2024 AstraZeneca PLC paid $ 0.985 per share dividend to its current shareholders | |
| Latest headline from zacks.com: Astrazeneca Could Be a Great Choice |
- Analyzing AstraZeneca PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AstraZeneca PLC's stock is overvalued or undervalued compared to its peers.
- Examining AstraZeneca PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AstraZeneca PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AstraZeneca PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AstraZeneca PLC's stock. These opinions can provide insight into AstraZeneca PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.059 | Dividend Share 2.9 | Earnings Share 1.91 | Revenue Per Share 2.4547 | Quarterly Revenue Growth 0.073 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.